Ins and outs of therapy in limb girdle muscular dystrophies

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 9, 2007, Pages 1608-1624

  Danièle, Nathalie ^a   Richard, Isabelle ^a   Bartoli, Marc ^a  

^a GÉNÉTHON   (France)

Author keywords

Cell and pharmacological therapy; Gene; Limb girdle muscular dystrophy; Skeletal muscle

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CALCIUM; CAVEOLIN 3; CORTICOSTEROID; DYSFERLIN; MUSCLE PROTEIN; MUTANT PROTEIN; PROTEASOMAL PROTEIN; PROTEASOME INHIBITOR; PROTEIN LGMD1A; PROTEIN LGMD1B; RECOMBINANT PROTEIN; SARCOGLYCAN; SARCOLEMMA PROTEIN; SARCOMERIC PROTEIN; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

AUTOSOMAL DOMINANT INHERITANCE; BLOOD CELL; CELL THERAPY; CELL VIABILITY; CLINICAL FEATURE; DUCHENNE MUSCULAR DYSTROPHY; GENE FUNCTION; GENE MUTATION; GENE TRANSFER; GENE VECTOR; GENETIC DISORDER; HEMATOPOIETIC STEM CELL; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE MASS; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; RECESSIVE INHERITANCE; REVIEW; STEM CELL TRANSPLANTATION; UMBILICAL CORD;

RODENTIA;

EID: 34447638686     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.02.005     Document Type: Review

References (144)

1. Albor A., El-Hizawi S., Horn E.J., Laederich M., Frosk P., Wrogemann K., et al. The interaction of Piasy with Trim32, an E3-ubiquitin ligase mutated in limb-girdle muscular dystrophy type 2H, promotes Piasy degradation and regulates UVB-induced keratinocyte apoptosis through NFkappaB. J. Biol. Chem. 281 (2006) 25850-25866
2. Alderton J.M., and Steinhardt R.A. Calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. J. Biol. Chem. 275 (2000) 9452-9460
3. Allamand V., Donahue K.M., Straub V., Davisson R.L., Davidson B.L., and Campbell K.P. Early adenovirus-mediated gene transfer effectively prevents muscular dystrophy in alpha-sarcoglycan-deficient mice. Gene Ther. 7 (2000) 1385-1391
4. Allikian M.J., Hack A.A., Mewborn S., Mayer U., and McNally E.M. Genetic compensation for sarcoglycan loss by integrin alpha7beta1 in muscle. J. Cell Sci. 117 (2004) 3821-3830
5. Balci B., Uyanik G., Dincer P., Gross C., Willer T., Talim B., et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul. Disord. 15 (2005) 271-275
6. Bansal D., Miyake K., Vogel S.S., Groh S., Chen C.C., Williamson R., et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423 (2003) 168-172
7. Bartoli M., Bourg N., Stockholm D., Raynaud F., Delevaque A., Han Y., et al. A mice model for monitoring calpain activity in physiological and pathological conditions. J. Biol. Chem. (2006)
8. Bartoli M., Poupiot J., Goyenvalle A., Perez N., Garcia L., Danos O., et al. Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies. Gene Ther. 13 (2006) 20-28
9. Bartoli M., Poupiot J., Vulin A., Fougerousse F., Arandel L., Daniele N., et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not α-sarcoglycan deficiency. Gene Ther. (2007) in press
10. Bartoli M., Roudaut C., Martin S., Fougerousse F., Suel L., Poupiot J., et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol. Ther. 13 (2006) 250-259
11. Barton-Davis E.R., Cordier L., Shoturma D.I., Leland S.E., and Sweeney H.L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104 (1999) 375-381
12. Barton E.R., Morris L., Musaro A., Rosenthal N., and Sweeney H.L. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 157 (2002) 137-148
13. Bashir R., Britton S., Strachan T., Keers S., Vafiadaki E., Lako M., et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat. Genet. 20 (1998) 37-42
14. Basta M., and Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94 (1994) 1729-1735
15. Betto R., Senter L., Ceoldo S., Tarricone E., Biral D., and Salviati G. Ecto-ATPase activity of alpha-sarcoglycan (adhalin). J. Biol. Chem. 274 (1999) 7907-7912
16. Blake D.J., Weir A., Newey S.E., and Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82 (2002) 291-329
17. Bogdanovich S., Krag T.O., Barton E.R., Morris L.D., Whittemore L.A., Ahima R.S., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 (2002) 418-421
18. Bogdanovich S., Perkins K.J., Krag T.O., Whittemore L.A., and Khurana T.S. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J. 19 (2005) 543-549
19. Bönnemann C.G., Modi R., Noguchi S., Mizuno Y., Yoshida M., Gussoni E., et al. ß-Sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat. Genet. 11 (1995) 266-273
20. Brockington M., Yuva Y., Prandini P., Brown S.C., Torelli S., Benson M.A., et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum. Mol. Genet. 10 (2001) 2851-2859
21. Bushby K., and Straub V. Nonmolecular treatment for muscular dystrophies. Curr. Opin. Neurol. 18 (2005) 511-518
22. Bushby K.M., and Beckmann J.S. The limb-girdle muscular dystrophies-Proposal for a new nomenclature. Neuromuscul. Disord. 5 (1995) 337-343
23. Cordier L., Gao G.P., Hack A.A., McNally E.M., Wilson J.M., Chirmule N., et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum. Gene Ther. 12 (2001) 205-215
24. Cordier L., Hack A.A., Scott M.O., Barton-Davis E.R., Gao G., Wilson J.M., et al. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol. Ther. 1 (2000) 119-129
25. Davies K.E., and Nowak K.J. Molecular mechanisms of muscular dystrophies: old and new players. Nat. Rev. Mol. Cell Biol. 7 (2006) 762-773
26. Dressman D., Araishi K., Imamura M., Sasaoka T., Liu L.A., Engvall E., et al. Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity. Hum. Gene Ther. 13 (2002) 1631-1646
27. Duguez S., Bartoli M., and Richard I. Calpain 3: a key regulator of the sarcomere?. FEBS J. 273 (2006) 3427-3436
28. Ervasti J.M., and Campbell K.P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122 (1993) 809-823
29. Esapa C.T., Benson M.A., Schroder J.E., Martin-Rendon E., Brockington M., Brown S.C., et al. Functional requirements for fukutin-related protein in the Golgi apparatus. Hum. Mol. Genet. 11 (2002) 3319-3331
30. Ettinger A.J., Feng G., and Sanes J.R. epsilon-Sarcoglycan, a broadly expressed homologue of the gene mutated in limb-girdle muscular dystrophy 2D. J. Biol. Chem. 272 (1997) 32534-32538
31. Fardeau M., Hillaire D., Mignard C., Feingold N., Feingold J., Mignard D., et al. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 119 Pt 1 (1996) 295-308
32. Fougerousse F., Bartoli M., Poupiot J., Arandel L., Durand M., Guerchet N., et al. Phenotypic correction of α-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector. Mol. Ther. 15 (2007) 53-61
33. Fridell R.A., Harding L.S., Bogerd H.P., and Cullen B.R. Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins. Virology 209 (1995) 347-357
34. Frosk P., Weiler T., Nylen E., Sudha T., Greenberg C.R., Morgan K., et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am. J. Hum. Genet. 70 (2002) 663-672
35. Galbiati F., Volonte D., Minetti C., Bregman D.B., and Lisanti M.P. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutants and rescues wild-type caveolin-3. J. Biol. Chem. 275 (2000) 37702-37711
36. Galbiati F., Volonte D., Minetti C., Chu J.B., and Lisanti M.P. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C) Retention of LGMD-1C caveolin-3 mutants within the golgi complex. J. Biol. Chem. 274 (1999) 25632-25641
37. Galvez B.G., Sampaolesi M., Brunelli S., Covarello D., Gavina M., Rossi B., et al. Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. J. Cell Biol. 174 (2006) 231-243
38. Gao G.P., Alvira M.R., Wang L., Calcedo R., Johnston J., and Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11854-11859
39. Garvey S.M., Miller S.E., Claflin D.R., Faulkner J.A., and Hauser M.A. Transgenic mice expressing the myotilin T57I mutation unite the pathology associated with LGMD1A and MFM. Hum. Mol. Genet. 15 (2006) 2348-2362
40. Gilbert R., Nalbanoglu J., Tinsley J.M., Massie B., Davies K.E., and Karpati G. Efficient utrophin expression following adenovirus gene transfer in dystrophic muscle. Biochem. Biophys. Res. Commun. 242 (1998) 244-247
41. Gillis J.M. An attempt of gene therapy in Duchenne muscular dystrophy: overexpression of utrophin in transgenic mdx mice. Acta Neurol. Belg. 100 (2000) 146-150
42. Godfrey C., Escolar D., Brockington M., Clement E.M., Mein R., Jimenez-Mallebrera C., et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann. Neurol. (2006)
43. Gontier Y., Taivainen A., Fontao L., Sonnenberg A., van der Flier A., Carpen O., et al. The Z-disc proteins myotilin and FATZ-1 interact with each other and are connected to the sarcolemma via muscle-specific filamins. J. Cell Sci. 118 (2005) 3739-3749
44. Goyenvalle A., Vulin A., Fougerousse F., Leturcq F., Kaplan J.C., Garcia L., et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306 (2004) 1796-1799
45. Grassi F., Pagani F., Spinelli G., De Angelis L., Cossu G., and Eusebi F. Fusion-independent expression of functional ACh receptors in mouse mesoangioblast stem cells contacting muscle cells. J. Physiol. 560 (2004) 479-489
46. Greelish J.P., Su L.T., Lankford E.B., Burkman J.M., Chen H., Konig S.K., et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat. Med. 5 (1999) 439-443
47. Gross D.A., Leboeuf M., Gjata B., Danos O., and Davoust J. CD4 + CD25 + regulatory T cells inhibit immune-mediated transgene rejection. Blood 102 (2003) 4326-4328
48. Gruenbaum Y., Margalit A., Goldman R.D., Shumaker D.K., and Wilson K.L. The nuclear lamina comes of age. Nat. Rev. Mol. Cell Biol. 6 (2005) 21-31
49. Guglieri M., Magri F., and Comi G.P. Molecular etiopathogenesis of limb girdle muscular and congenital muscular dystrophies: boundaries and contiguities. Clin. Chim. Acta 361 (2005) 54-79
50. Gussoni E., Pavlath G.K., Lanctot A.M., Sharma K.R., Miller R.G., Steinman L., et al. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 356 (1992) 435-438
51. Guttinger M., Tafi E., Battaglia M., Coletta M., and Cossu G. Allogeneic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice. Exp. Cell Res. (2006)
52. Hackman P., Vihola A., Haravuori H., Marchand S., Sarparanta J., De Seze J., et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am. J. Hum. Genet. 71 (2002) 492-500
53. Hagiwara H., Ohsawa Y., Asakura S., Murakami T., Teshima T., and Sunada Y. Bone marrow transplantation improves outcome in a mouse model of congenital muscular dystrophy. FEBS Lett. 580 (2006) 4463-4468
54. Hauser M.A., Horrigan S.K., Salmikangas P., Torian U.M., Viles K.D., Dancel R., et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum. Mol. Genet. 9 (2000) 2141-2147
55. Holt K.H., and Campbell K.P. Assembly of the sarcoglycan complex Insights for muscular dystrophy. J. Biol. Chem. 273 (1998) 34667-34670
56. Holt K.H., Lim L.E., Straub V., Venzke D.P., Duclos F., Anderson R.D., et al. Functional rescue of the sarcoglycan complex in the BIO 14 6 hamster using delta-sarcoglycan gene transfer. Mol. Cell. 1 (1998) 841-848
57. Horn E.J., Albor A., Liu Y., El-Hizawi S., Vanderbeek G.E., Babcock M., et al. RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis 25 (2004) 157-167
58. Howard M.T., Shirts B.H., Petros L.M., Flanigan K.M., Gesteland R.F., and Atkins J.F. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol. 48 (2000) 164-169
59. Imamura M., Mochizuki Y., Engvall E., and Takeda S. Epsilon-sarcoglycan compensates for lack of alpha-sarcoglycan in a mouse model of limb-girdle muscular dystrophy. Hum. Mol. Genet. 14 (2005) 775-783
60. Iwata Y., Katanosaka Y., Arai Y., Komamura K., Miyatake K., and Shigekawa M. A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel. J. Cell Biol. 161 (2003) 957-967
61. Iwata Y., Katanosaka Y., Shijun Z., Kobayashi Y., Hanada H., Shigekawa M., et al. Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. Biochem. Pharmacol. 70 (2005) 740-751
62. Khurana T.S., and Davies K.E. Pharmacological strategies for muscular dystrophy. Nat. Rev. Drug Discov. 2 (2003) 379-390
63. Kim D.S., Hayashi Y.K., Matsumoto H., Ogawa M., Noguchi S., Murakami N., et al. POMT1 mutation results in defective glycosylation and loss of laminin-binding activity in alpha-DG. Neurology 62 (2004) 1009-1011
64. Koenig M., Hoffman E.P., Bertelson C.J., Monaco A.P., Feener C., and Kunkel L.M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50 (1987) 509-517
65. Kong K.Y., Ren J., Kraus M., Finklestein S.P., and Brown Jr. R.H. Human umbilical cord blood cells differentiate into muscle in sjl muscular dystrophy mice. Stem Cells 22 (2004) 981-993
66. Kramerova I., Kudryashova E., Tidball J.G., and Spencer M.J. Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Hum. Mol. Genet. 13 (2004) 1373-1388
67. Kudryashova E., Kudryashov D., Kramerova I., and Spencer M.J. Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. J. Mol. Biol. 354 (2005) 413-424
68. Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E., et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science 308 (2005) 1599-1603
69. Langlois M.A., Boniface C., Wang G., Alluin J., Salvaterra P.M., Puymirat J., et al. Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J. Biol. Chem. 280 (2005) 16949-16954
70. Lapidos K.A., Chen Y.E., Earley J.U., Heydemann A., Huber J.M., Chien M., et al. Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. J. Clin. Invest. 114 (2004) 1577-1585
71. Li J., Dressman D., Tsao Y.P., Sakamoto A., Hoffman E.P., and Xiao X. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther. 6 (1999) 74-82
72. Lim L.E., Duclos F., Broux O., Bourg N., Sunada Y., Allamand V., et al. Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat. Genet. 11 (1995) 257-265
73. Liu J., Aoki M., Illa I., Wu C., Fardeau M., Angelini C., et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 20 (1998) 31-36
74. Liu L.A., and Engvall E. Sarcoglycan isoforms in skeletal muscle. J. Biol. Chem. 274 (1999) 38171-38176
75. Mallouk N., Jacquemond V., and Allard B. Elevated subsarcolemmal Ca2+ in mdx mouse skeletal muscle fibers detected with Ca2+-activated K+ channels. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4950-4955
76. Mann C.J., Honeyman K., Cheng A.J., Ly T., Lloyd F., Fletcher S., et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 42-47
77. Mayans O., van der Ven P.F., Wilm M., Mues A., Young P., Furst D.O., et al. Structural basis for activation of the titin kinase domain during myofibrillogenesis. Nature 395 (1998) 863-869
78. McNally E.M., Ly C.T., and Kunkel L.M. Human epsilon-sarcoglycan is highly related to alpha-sarcoglycan (adhalin), the limb girdle muscular dystrophy 2D gene. FEBS Lett. 422 (1998) 27-32
79. Messina D.N., Speer M.C., Pericak-Vance M.A., and McNally E.M. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am. J. Hum. Genet. 61 (1997) 909-917
80. Milic A., Daniele N., Lochmueller H., Mora M., Comi G.P., Moggio M., et al. A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Neuromuscul. Disord. 17 (2007) 148-156
81. Minasi M.G., Riminucci M., De Angelis L., Borello U., Berarducci B., Innocenzi A., et al. The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 129 (2002) 2773-2783
82. Minetti C., Sotgia F., Bruno C., Scartezzini P., Broda P., Bado M., et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 18 (1998) 365-368
83. Minetti G.C., Colussi C., Adami R., Serra C., Mozzetta C., Parente V., et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 12 (2006) 1147-1150
84. Miura P., and Jasmin B.J. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?. Trends Mol. Med. 12 (2006) 122-129
85. Mogi C., Miyai S., Nishimura Y., Fukuro H., Yokoyama K., Takaki A., et al. Differentiation of skeletal muscle from pituitary folliculo-stellate cells and endocrine progenitor cells. Exp. Cell Res. 292 (2004) 288-294
86. Montarras D., Morgan J., Collins C., Relaix F., Zaffran S., Cumano A., et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science 309 (2005) 2064-2067
87. Moreira E.S., Wiltshire T.J., Faulkner G., Nilforoushan A., Vainzof M., Suzuki O.T., et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat. Genet. 24 (2000) 163-166
88. Moza M., Mologni L., Trokovic R., Faulkner G., Partanen J., and Carpen O. Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice. Mol. Cell Biol. (2006)
89. Muchir A., Bonne G., van der Kooi A.J., van Meegen M., Baas F., Bolhuis P.A., et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum. Mol. Genet. 9 (2000) 1453-1459
90. Mueller G.M., O'Day T., Watchko J.F., and Ontell M. Effect of injecting primary myoblasts versus putative muscle-derived stem cells on mass and force generation in mdx mice. Hum. Gene Ther. 13 (2002) 1081-1090
91. Muntoni F. Journey into muscular dystrophies caused by abnormal glycosylation. Acta Myol. 23 (2004) 79-84
92. Nicholas G., Thomas M., Langley B., Somers W., Patel K., Kemp C.F., et al. Titin-cap associates with, and regulates secretion of Myostatin. J. Cell Physiol. 193 (2002) 120-131
93. Nigro V., de Sa Moreira E., Piluso G., Vainzof M., Belsito A., Politano L., et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat. Genet. 14 (1996) 195-198
94. Noguchi S., McNally E.M., Ben Othmane K., Hagiwara Y., Mizuno Y., Yoshida M., et al. Mutations in the dystrophin-associated protein γ-sarcoglycan in chromosome 13 muscular dystrophy. Science 270 (1995) 819-822
95. Ohsawa Y., Hagiwara H., Nakatani M., Yasue A., Moriyama K., Murakami T., et al. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J. Clin. Invest. (2006)
96. Ono Y., Shimada H., Sorimachi H., Richard I., Saido T.C., Beckmann J.S., et al. Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A. J. Biol. Chem. 273 (1998) 17073-17078
97. Ozawa E., Mizuno Y., Hagiwara Y., Sasaoka T., and Yoshida M. Molecular and cell biology of the sarcoglycan complex. Muscle Nerve 32 (2005) 563-576
98. Palenzuela L., Andreu A.L., Gamez J., Vila M.R., Kunimatsu T., Meseguer A., et al. A novel autosomal dominant limb-girdle muscular dystrophy (LGMD 1F) maps to 7q32 1-32.2. Neurology 61 (2003) 404-406
99. Parsons S.A., Millay D.P., Sargent M.A., McNally E.M., and Molkentin J.D. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am. J. Pathol. 168 (2006) 1975-1985
100. Partridge T.A., and Davies K.E. Myoblast-based gene therapies. Br. Med. Bull. 51 (1995) 123-137
101. Rando T.A. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24 (2001) 1575-1594
102. Razani B., Zhang X.L., Bitzer M., von Gersdorff G., Bottinger E.P., and Lisanti M.P. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J. Biol. Chem. 276 (2001) 6727-6738
103. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A.J., and Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell Biol. 23 (2003) 7230-7242
104. Richard I., Broux O., Allamand V., Fougerousse F., Chiannilkulchai N., Bourg N., et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81 (1995) 27-40
105. Roberds S.L., Leturcq F., Allamand V., Piccolo F., Jeanpierre M., Anderson R.D., et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 78 (1994) 625-633
106. Robert V., Massimino M.L., Tosello V., Marsault R., Cantini M., Sorrentino V., et al. Alteration in calcium handling at the subcellular level in mdx myotubes. J. Biol. Chem. 276 (2001) 4647-4651
107. Salah-Mohellibi N., Millet G., Andre-Schmutz I., Desforges B., Olaso R., Roblot N., et al. Bone marrow transplantation attenuates the myopathic phenotype of a muscular mouse model of spinal muscular atrophy. Stem Cells (2006)
108. Salmikangas P., Mykkanen O.M., Gronholm M., Heiska L., Kere J., and Carpen O. Myotilin, a novel sarcomeric protein with two Ig-like domains, is encoded by a candidate gene for limb-girdle muscular dystrophy. Hum. Mol. Genet. 8 (1999) 1329-1336
109. Salmikangas P., van der Ven P.F., Lalowski M., Taivainen A., Zhao F., Suila H., et al. Myotilin, the limb-girdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly. Hum. Mol. Genet. 12 (2003) 189-203
110. Sampaolesi M., Blot S., D/'Antona G., Granger N., Tonlorenzi R., Innocenzi A., et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature (2006)
111. Sampaolesi M., Torrente Y., Innocenzi A., Tonlorenzi R., D'Antona G., Pellegrino M.A., et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301 (2003) 487-492
112. Sarugaser R., Lickorish D., Baksh D., Hosseini M.M., and Davies J.E. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 23 (2005) 220-229
113. Sciorati C., Galvez B., Brunelli S., Tagliafico E., Ferrari S., Cossu G., et al. Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy. J. Cell Sci. 119 (2006) 5114-5123
114. Shiga K., Yoshioka H., Matsumiya T., Kimura I., Takeda S., and Imamura M. Zeta-sarcoglycan is a functional homologue of gamma-sarcoglycan in the formation of the sarcoglycan complex. Exp. Cell. Res. 312 (2006) 2083-2092
115. Sinnreich M., Therrien C., and Karpati G. Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 66 (2006) 1114-1116
116. Skuk D., Goulet M., Roy B., and Tremblay J.P. Myoblast transplantation in whole muscle of nonhuman primates. J. Neuropathol. Exp. Neurol. 59 (2000) 197-206
117. Speer M.C., Vance J.M., Grubber J.M., Lennon Graham F., Stajich J.M., Viles K.D., et al. Identification of a new autosomal dominant limb-girdle muscular dystrophy locus on chromosome 7. Am. J. Hum. Genet. 64 (1999) 556-562
118. Spencer M.J., and Mellgren R.L. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum. Mol. Genet. 11 (2002) 2645-2655
119. Spuler, et al. Proceedings of the 58th annual meeting of the American academy of neurology, April 6 (2006)
120. Starling A., Kok F., Passos-Bueno M.R., Vainzof M., and Zatz M. A new form of autosomal dominant limb-girdle muscular dystrophy (LGMD1G) with progressive fingers and toes flexion limitation maps to chromosome 4p21. Eur. J. Hum. Genet. 12 (2004) 1033-1040
121. Straub V., Ettinger A.J., Durbeej M., Venzke D.P., Cutshall S., Sanes J.R., et al. Epsilon-sarcoglycan replaces alpha-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex. J. Biol. Chem. 274 (1999) 27989-27996
122. Sunada Y., Ohi H., Hase A., Ohi H., Hosono T., Arata S., et al. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum. Mol. Genet. 10 (2001) 173-178
123. Tang Z., Scherer P.E., Okamoto T., Song K., Chu C., Kohtz D.S., et al. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J. Biol. Chem. 271 (1996) 2255-2261
124. Taveau M., Bourg N., Sillon G., Roudaut C., Bartoli M., and Richard I. Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. Mol. Cell Biol. 23 (2003) 9127-9135
125. Tinsley J.M., Potter A.C., Phelps S.R., Fisher R., Trickett J.I., and Davies K.E. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384 (1996) 349-353
126. Tintut Y., Alfonso Z., Saini T., Radcliff K., Watson K., Bostrom K., et al. Multilineage potential of cells from the artery wall. Circulation 108 (2003) 2505-2510
127. Tskhovrebova L., and Trinick J. Titin: properties and family relationships. Nat. Rev. Mol. Cell Biol. 4 (2003) 679-689
128. Valle G., Faulkner G., De Antoni A., Pacchioni B., Pallavicini A., Pandolfo D., et al. Telethonin, a novel sarcomeric protein of heart and skeletal muscle. FEBS Lett. 415 (1997) 163-168
129. van Denderen B.J., Pearse M.J., Katerelos M., Nottle M.B., Du Z.T., Aminian A., et al. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. Transplantation 61 (1996) 582-588
130. van der Ven P.F., Wiesner S., Salmikangas P., Auerbach D., Himmel M., Kempa S., et al. Indications for a novel muscular dystrophy pathway. gamma-Filamin, the muscle-specific filamin isoform, interacts with myotilin. J. Cell Biol. 151 (2000) 235-248
131. Wagner K.R., Hamed S., Hadley D.W., Gropman A.L., Burstein A.H., Escolar D.M., et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. 49 (2001) 706-711
132. Wang L., Dobrzynski E., Schlachterman A., Cao O., and Herzog R.W. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 105 (2005) 4226-4234
133. Watkins S.C., Hoffman E.P., Slayter H.S., and Kunkel L.M. Immunoelectron microscopic localization of dystrophin in myofibres. Nature 333 (1988) 863-866
134. Weiss M.L., Medicetty S., Bledsoe A.R., Rachakatla R.S., Choi M., Merchav S., et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 24 (2006) 781-792
135. Wenzel K., Zabojszcza J., Carl M., Taubert S., Lass A., Harris C.L., et al. Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. J. Immunol. 175 (2005) 6219-6225
136. Wheeler M.T., Zarnegar S., and McNally E.M. Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum. Mol. Genet. 11 (2002) 2147-2154
137. Xiao W., Chirmule N., Berta S.C., McCullough B., Gao G., and Wilson J.M. Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73 (1999) 3994-4003
138. Xiao X., Li J., Tsao Y.P., Dressman D., Hoffman E.P., and Watchko J.F. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J. Virol. 74 (2000) 1436-1442
139. Yoshida T., Pan Y., Hanada H., Iwata Y., and Shigekawa M. Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes. J. Biol. Chem. 273 (1998) 1583-1590
140. Zaiss A.K., and Muruve D.A. Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 5 (2005) 323-331
141. Zatz M., and Starling A. Calpains and disease. N. Engl. J. Med. 352 (2005) 2413-2423
142. Zhu T., Zhou L., Mori S., Wang Z., McTiernan C.F., Qiao C., et al. Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 112 (2005) 2650-2659
143. Zhu X., Hadhazy M., Groh M.E., Wheeler M.T., Wollmann R., and McNally E.M. Overexpression of gamma-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of Sarcoglycan assembly. J. Biol. Chem. 276 (2001) 21785-21790
144. Zubrzycka-Gaarn E.E., Bulman D.E., Karpati G., Burghes A.H., Belfall B., Klamut H.J., et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 333 (1988) 466-469